Analysis from the Johns Hopkins School of Medicine provided psilocybin advocates with some potentially excellent news. Research into the drug's safety and abuse potential concluded that Schedule IV status, which includes medications like sleeping aids, might be a more appropriate classification if psilocybin passes phase III clinical trials.
The analysis sought to further gauge the safety and efficacy of psilocybin mushrooms after previous findings highlighted its potential in treating cancer-related psychiatric distress and substance abuse. While noting that harms existed when self-medicated, the analysis explained that is not the case in a professional medical setting.
"Scope of use and associated harms are low compared to prototypical abused drugs, and the medical model addresses these concerns with dose control, patient screening, preparation and follow-up, and session supervision in a medical facility," the study concluded.
Analysis of studies on both humans and animals revealed a low potential for psilocybin abuse, noting that most humans will only use it a few times in their lives. In a definitive statement, the study also concluded that the adverse effects of taking shrooms are manageable "when administered according to risk management approaches."
Clinical studies will continue, but conclusions from a leading institution like Johns Hopkins provides psilocybin proponents with needed conspicuous support as they continue to push for further studies and potential reclassification.